Indian Pharma May Shift Tariff Burden To US Buyers

Indian pharma firms may be forced to hike drug prices in the US if Trump enforces a 200% import tariff on pharmaceuticals, sources said. Operating on low margins, smaller companies could face severe strain. The US, a key market for Indian drugmakers, currently imposes no duty on Indian drugs, which contribute 30-40% of their revenue.